Pathos AI

AI-driven drug developer that picks clinical assets and runs trials using probability-of-success models, with a focus on oncology.

View on the globe

$602MEquity raised in 2025–20262025 $365M · 2026 $237M · 2 equity rounds
$664MEquity raised, all time3 equity rounds sourced so far
$3BLatest valuationpost-money, as reported

Rounds over time log-scaled amounts

Funding history: 3 rounds from 29 Oct 2024 to 23 Oct 2026, $664M equity disclosed, latest valuation $3B. Earlier rounds exist but are not sourced.29 Oct 2024: Series C, $62M, valued at $600M; 15 May 2025: Series D, $365M, valued at $1.6B; 23 Oct 2026: Series E, $237M, valued at $3B$10M$30M$100M$300M$1B$3B$10BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 2021202520262027Equity roundPost-money valuation29 Oct 2024 · Series C · valued at $600M15 May 2025 · Series D · valued at $1.6B23 Oct 2026 · Series E · valued at $3B15 May 2025 · Series D · $365M at $1.6B23 Oct 2026 · Series E · $237M at $3B · led by Bristol Myers Squibb29 Oct 2024 · Series C · $62M at $600M · led by NEA$3BSeries D · $365MSeries E · $237MSeries C · $62M
Funding history: 3 rounds from 29 Oct 2024 to 23 Oct 2026, $664M equity disclosed, latest valuation $3B. Earlier rounds exist but are not sourced.29 Oct 2024: Series C, $62M, valued at $600M; 15 May 2025: Series D, $365M, valued at $1.6B; 23 Oct 2026: Series E, $237M, valued at $3B$10M$30M$100M$300M$1B$3B$10BEarlier rounds exist but are not sourced yetearlier rounds not sourced’21202520262027Equity roundValuation29 Oct 2024 · Series C · valued at $600M15 May 2025 · Series D · valued at $1.6B23 Oct 2026 · Series E · valued at $3B15 May 2025 · Series D · $365M at $1.6B23 Oct 2026 · Series E · $237M at $3B · led by Bristol Myers Squibb29 Oct 2024 · Series C · $62M at $600M · led by NEA$3B$365M$237M$62M

Funding history 3 rounds · 5 sources · newest first

Earlier rounds not yet sourced. Pathos AI was founded in 2021 and raised before 29 Oct 2024; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series E
    Amount$237M
    Post-money$3B
    ✓ Confirmed
    Lead
    Bristol Myers Squibb
    Note
    Led by Bristol Myers Squibb with unnamed existing investors; announced alongside BMS and Tempus AI collaborations. Approximately $3B post-money.
    Sources
  2. Series D
    Amount$365M
    Post-money$1.6B
    ✓ Confirmed
    Note
    About $1.6B post-money per the company release; investors were not named in the release or in the reports.
    Sources
  3. Series C
    Amount$62M
    Post-money$600M
    ✓ Confirmed
    Lead
    NEA
    Also
    Revolution Growth, Lightbank, Builders VC
    Note
    Oversubscribed; $600M post-money. Company stated total funding of $102M including this round; earlier rounds not sourced here. Release datelined Chicago.
    Sources
  4. Earlier rounds not yet sourced

Investors 5

  • Bristol Myers Squibb1
  • NEA1
  • Builders VC
  • Lightbank
  • Revolution Growth

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the New York hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Pathos AI and its logo are trademarks of their owners, used here for identification only.